TRVI

Trevi Therapeutics, Inc.

Price Chart

Latest Quote

$16.37

+0.97 (+6.30%)

Current Price

Previous Close	$15.40
Open	$15.56
Day High	$16.80
Day Low	$15.41
Volume	2,675,285

Fetched: 2026-06-18T08:49:09

Stock Information

Shares Outstanding	141.98M
Total Debt	$682K
Cash Equivalents	$171.78M
Net Income	$-45.61M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$2.32B
EPS (TTM)	$-0.32
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$2.02B
Income	$-45.61M
Book/sh	$1.34
Cash/sh	$1.21
Employees	34

Financial Ratios

Quick Ratio	24.30
Current Ratio	24.75
Debt/Eq	0.40

Returns & Margins

ROA	-23.02%
ROE	-33.59%

Ownership

Insider Ownership	0.63%
Institutional Ownership	98.30%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-29.35
P/B	12.22

Analyst Data

Recommendation	none
Target Price	$23.90

Technical Indicators

SMA20	$14.12
SMA50	$14.18
SMA200	$11.77
RSI	67.45
ATR	0.7268

Shares Float	118.77M
Short Float	10.62%
Short Ratio	9.52
Volatility	1.05
Rel Volume	2.21

Performance History

Week	+22.16%
Month	+21.89%
Quarter	+53.13%
6 Months	+29.82%
YTD	+37.68%
Year	+158.41%
3 Years	+539.45%
5 Years	+644.09%
10 Years	+107.48%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-17	$16.37	2,675,600
2026-06-16	$15.40	3,430,100
2026-06-15	$14.66	1,351,100
2026-06-12	$14.21	1,513,500
2026-06-11	$13.46	641,900
2026-06-10	$13.40	931,500
2026-06-09	$13.59	1,318,600
2026-06-08	$13.50	697,500
2026-06-05	$13.33	729,300
2026-06-04	$13.93	877,500
2026-06-03	$13.45	720,200
2026-06-02	$13.50	925,900
2026-06-01	$13.95	1,125,100
2026-05-29	$14.14	1,006,300
2026-05-28	$14.45	922,500
2026-05-27	$14.45	773,500
2026-05-26	$14.38	1,077,400
2026-05-22	$14.13	1,323,200
2026-05-21	$14.16	957,400
2026-05-20	$13.88	1,262,800
2026-05-19	$13.24	1,216,400
2026-05-18	$13.43	1,410,100

About Trevi Therapeutics, Inc.

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.

📰 Latest News

Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.

Motley Fool • 2026-06-03T14:04:22Z

Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030

MarketBeat • 2026-05-09T09:05:20Z

Trevi Therapeutics, Inc. Q1 2026 Earnings Call Summary

Moby • 2026-05-06T16:58:09Z

Why Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030

Simply Wall St. • 2026-05-06T16:14:32Z

Trevi Therapeutics Q1 Earnings Call Highlights

MarketBeat • 2026-05-06T04:08:23Z

Did Trevi’s US$173 Million Raise and Share Expansion Just Reshape Trevi Therapeutics' (TRVI) Investment Narrative?

Simply Wall St. • 2026-04-22T13:06:59Z

Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday as Investors Take Positions Amid Corporate Earnings

MT Newswires • 2026-04-17T12:22:37Z

A Look At Trevi Therapeutics (TRVI) Valuation After FDA End Of Phase 2 Milestone For IPF Chronic Cough

Simply Wall St. • 2026-04-05T10:04:52Z

As Terns Stock Soars 1,400%, What Does One Fund's $5.2 Million Sale Signal to Investors?

Motley Fool • 2026-03-23T16:07:27Z

Trevi Therapeutics Q4 Earnings Call Highlights

MarketBeat • 2026-03-18T22:36:07Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$0	$4,000	$391,000	$1,163,000
Total Expenses	$49,328,000	$51,524,000	$33,923,000	$29,907,000
Other Income Expense	$-31,000	$-15,000	$469,000	$142,000
Other Non Operating Income Expenses	$-31,000	$-15,000	$469,000	$289,000
Net Non Operating Interest Income Expense	$6,536,000	$3,598,000	$4,357,000	$577,000
Interest Expense Non Operating	$0	$4,000	$391,000	$1,163,000
Operating Expense	$49,328,000	$51,524,000	$33,923,000	$29,907,000
General And Administrative Expense	$15,850,000	$12,147,000	$10,240,000	$10,073,000
Total Other Finance Cost	-	-	-	$383,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-42,759,000	$-47,911,000	$-29,065,000	$-29,152,000
Net Interest Income	$6,536,000	$3,598,000	$4,357,000	$577,000
Interest Income	$6,536,000	$3,602,000	$4,748,000	$1,740,000
Normalized Income	$-42,759,000	$-47,911,000	$-29,065,000	$-29,005,147
Net Income From Continuing And Discontinued Operation	$-42,759,000	$-47,911,000	$-29,065,000	$-29,152,000
Total Operating Income As Reported	$-49,328,000	$-51,524,000	$-33,923,000	$-29,907,000
Net Income Common Stockholders	$-42,759,000	$-47,911,000	$-29,065,000	$-29,152,000
Net Income	$-42,759,000	$-47,911,000	$-29,065,000	$-29,152,000
Net Income Including Noncontrolling Interests	$-42,759,000	$-47,911,000	$-29,065,000	$-29,152,000
Net Income Continuous Operations	$-42,759,000	$-47,911,000	$-29,065,000	$-29,152,000
Pretax Income	$-42,823,000	$-47,941,000	$-29,097,000	$-29,188,000
Interest Income Non Operating	$6,536,000	$3,602,000	$4,748,000	$1,740,000
Operating Income	$-49,328,000	$-51,524,000	$-33,923,000	$-29,907,000
Per Share
Diluted EPS	$-0.32	$-0.47	$-0.29	$-0.45
Basic EPS	$-0.32	$-0.47	$-0.29	$-0.45
Other
Tax Effect Of Unusual Items	$0	$0	$0	$-147
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-42,679,000	$-47,790,000	$-28,583,000	$-27,835,000
Reconciled Depreciation	$144,000	$147,000	$123,000	$43,000
EBITDA (Bullshit earnings)	$-42,679,000	$-47,790,000	$-28,583,000	$-27,982,000
EBIT	$-42,823,000	$-47,937,000	$-28,706,000	$-28,025,000
Diluted Average Shares	$134,747,198	$101,971,873	$99,033,373	$64,541,911
Basic Average Shares	$134,747,198	$101,971,873	$99,033,373	$64,541,911
Diluted NI Availto Com Stockholders	$-42,759,000	$-47,911,000	$-29,065,000	$-29,152,000
Tax Provision	$-64,000	$-30,000	$-32,000	$-36,000
Research And Development	$33,478,000	$39,377,000	$23,683,000	$19,834,000
Selling General And Administration	$15,850,000	$12,147,000	$10,240,000	$10,073,000
Other Gand A	$15,850,000	$12,147,000	$10,240,000	$10,073,000
Total Unusual Items	-	-	-	$-147,000
Total Unusual Items Excluding Goodwill	-	-	-	$-147,000
Gain On Sale Of Security	-	-	-	$-147,000

Fetched: 2026-06-17

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$183,244,000	$99,644,000	$82,547,000	$107,459,000
Total Assets	$193,439,000	$110,900,000	$89,403,000	$123,015,000
Total Non Current Assets	$1,783,000	$1,472,000	$1,856,000	$399,000
Other Non Current Assets	$928,000	$243,000	$297,000	$205,000
Current Assets	$191,656,000	$109,428,000	$87,547,000	$122,616,000
Other Current Assets	$2,133,000	$867,000	$955,000	$1,311,000
Prepaid Assets	$1,263,000	$939,000	$3,621,000	$795,000
Cash Cash Equivalents And Short Term Investments	$188,260,000	$107,622,000	$82,971,000	$120,510,000
Cash And Cash Equivalents	$18,914,000	$34,097,000	$32,397,000	$12,589,000
Receivables	-	-	-	-
Taxes Receivable	-	-	-	-
Debt
Total Debt	$753,000	$1,032,000	$1,338,000	$9,178,000
Long Term Debt And Capital Lease Obligation	$446,000	$747,000	$1,032,000	$2,153,000
Current Debt And Capital Lease Obligation	$307,000	$285,000	$306,000	$7,025,000
Long Term Debt	-	-	-	$2,151,000
Current Debt	-	-	-	$7,000,000
Other Current Borrowings	-	-	-	$7,000,000
Liabilities
Total Liabilities Net Minority Interest	$10,195,000	$11,256,000	$6,856,000	$15,556,000
Total Non Current Liabilities Net Minority Interest	$446,000	$747,000	$1,032,000	$2,156,000
Current Liabilities	$9,749,000	$10,509,000	$5,824,000	$13,400,000
Payables And Accrued Expenses	$6,696,000	$7,686,000	$3,904,000	$4,867,000
Payables	$3,911,000	$3,414,000	$1,809,000	$2,857,000
Accounts Payable	$3,911,000	$3,414,000	$1,809,000	$2,857,000
Other Non Current Liabilities	-	-	-	$3,000
Derivative Product Liabilities	-	-	-	-
Other Current Liabilities	-	-	-	-
Equity
Common Stock Equity	$183,244,000	$99,644,000	$82,547,000	$107,459,000
Total Equity Gross Minority Interest	$183,244,000	$99,644,000	$82,547,000	$107,459,000
Stockholders Equity	$183,244,000	$99,644,000	$82,547,000	$107,459,000
Gains Losses Not Affecting Retained Earnings	$148,000	$61,000	$-29,000	$-122,000
Other Equity Adjustments	$148,000	$61,000	$-29,000	$-122,000
Retained Earnings	$-329,804,000	$-287,045,000	$-239,134,000	$-210,069,000
Other
Ordinary Shares Number	$128,306,056	$93,602,631	$68,283,699	$59,943,430
Share Issued	$128,306,056	$93,602,631	$68,283,699	$59,943,430
Tangible Book Value	$183,244,000	$99,644,000	$82,547,000	$107,459,000
Invested Capital	$183,244,000	$99,644,000	$82,547,000	$116,610,000
Working Capital	$181,907,000	$98,919,000	$81,723,000	$109,216,000
Capital Lease Obligations	$753,000	$1,032,000	$1,338,000	$27,000
Total Capitalization	$183,244,000	$99,644,000	$82,547,000	$109,610,000
Additional Paid In Capital	$512,772,000	$386,534,000	$321,642,000	$317,590,000
Capital Stock	$128,000	$94,000	$68,000	$60,000
Common Stock	$128,000	$94,000	$68,000	$60,000
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$446,000	$747,000	$1,032,000	$2,000
Current Capital Lease Obligation	$307,000	$285,000	$306,000	$25,000
Pensionand Other Post Retirement Benefit Plans Current	$2,746,000	$2,538,000	$1,614,000	$1,508,000
Current Accrued Expenses	$2,785,000	$4,272,000	$2,095,000	$2,010,000
Net PPE	$855,000	$1,229,000	$1,559,000	$194,000
Accumulated Depreciation	$-359,000	$-228,000	$-134,000	$-225,000
Gross PPE	$1,214,000	$1,457,000	$1,693,000	$419,000
Leases	$29,000	$29,000	$29,000	$130,000
Construction In Progress	$1,000	$7,000	$17,000	$53,000
Other Properties	$677,000	$1,072,000	$1,343,000	$24,000
Machinery Furniture Equipment	$507,000	$349,000	$304,000	$212,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$169,346,000	$73,525,000	$50,574,000	$107,921,000

Fetched: 2026-06-17

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-42,101,000	$-38,291,000	$-31,847,000	$-28,334,000
Operating Activities
Operating Cash Flow	$-42,089,000	$-38,256,000	$-31,710,000	$-28,175,000
Cash Flow From Continuing Operating Activities	$-42,089,000	$-38,256,000	$-31,710,000	$-28,175,000
Operating Gains Losses	$7,000	-	$10,000	$147,000
Investing Activities
Capital Expenditure	$-12,000	$-35,000	$-137,000	$-159,000
Investing Cash Flow	$-94,107,000	$-21,528,000	$59,428,000	$-107,373,000
Cash Flow From Continuing Investing Activities	$-94,107,000	$-21,528,000	$59,428,000	$-107,373,000
Financing Activities
Issuance Of Capital Stock	$108,154,000	$61,146,000	$1,710,000	$105,410,000
Financing Cash Flow	$121,013,000	$61,484,000	$-7,910,000	$111,307,000
Cash Flow From Continuing Financing Activities	$121,013,000	$61,484,000	$-7,910,000	$111,307,000
Net Other Financing Charges	$-84,000	-	$-258,000	$-247,000
Net Common Stock Issuance	$108,154,000	$61,146,000	$1,710,000	$105,410,000
Common Stock Issuance	$108,154,000	$61,146,000	$1,710,000	$105,410,000
Other
Repayment Of Debt	$-11,000	$-126,000	$-9,504,000	$-5,833,000
Interest Paid Supplemental Data	$0	$4,000	$331,000	$594,000
End Cash Position	$18,914,000	$34,097,000	$32,397,000	$12,589,000
Beginning Cash Position	$34,097,000	$32,397,000	$12,589,000	$36,830,000
Changes In Cash	$-15,183,000	$1,700,000	$19,808,000	$-24,241,000
Proceeds From Stock Option Exercised	$12,954,000	$464,000	$142,000	$11,977,000
Net Issuance Payments Of Debt	$-11,000	$-126,000	$-9,504,000	$-5,833,000
Net Long Term Debt Issuance	$-11,000	$-126,000	$-9,504,000	$-5,833,000
Long Term Debt Payments	$-11,000	$-126,000	$-9,504,000	$-5,833,000
Net Investment Purchase And Sale	$-94,095,000	$-21,493,000	$59,565,000	$-107,214,000
Sale Of Investment	$76,567,000	$76,970,000	$69,497,000	$19,001,000
Purchase Of Investment	$-170,662,000	$-98,463,000	$-9,932,000	$-126,215,000
Net PPE Purchase And Sale	$-12,000	$-35,000	$-137,000	$-159,000
Purchase Of PPE	$-12,000	$-35,000	$-137,000	$-159,000
Change In Working Capital	$-3,491,000	$6,827,000	$-3,847,000	$-1,231,000
Change In Payables And Accrued Expense	$-2,013,000	$4,168,000	$-997,000	$-630,000
Change In Accrued Expense	$-1,415,000	$2,563,000	$52,000	$-639,000
Change In Payable	$-598,000	$1,605,000	$-1,049,000	$9,000
Change In Account Payable	$-598,000	$1,605,000	$-1,049,000	$9,000
Change In Prepaid Assets	$-1,478,000	$2,659,000	$-2,850,000	$-601,000
Other Non Cash Items	$463,000	$460,000	$947,000	$520,000
Stock Based Compensation	$5,185,000	$3,588,000	$2,247,000	$2,327,000
Amortization Of Securities	$-1,638,000	$-1,367,000	$-2,125,000	$-829,000
Depreciation Amortization Depletion	$144,000	$147,000	$123,000	$43,000
Depreciation And Amortization	$144,000	$147,000	$123,000	$43,000
Gain Loss On Sale Of PPE	$7,000	$0	$10,000	$0
Net Income From Continuing Operations	$-42,759,000	$-47,911,000	$-29,065,000	$-29,152,000
Net Short Term Debt Issuance	-	$0	$-9,409,000	-
Short Term Debt Payments	-	$0	$-9,409,000	-
Asset Impairment Charge	-	$0	$390,000	$0
Depreciation	-	-	-	$43,000
Gain Loss On Investment Securities	-	-	-	$147,000
Issuance Of Debt	-	-	-	-
Long Term Debt Issuance	-	-	-	-

Fetched: 2026-06-17